VEGF rs3025039和rs3025021多态性与胃癌组织中VEGF、COX-2表达的关系

目的研究血管内皮生长因子(VEGF)基因单核甘酸多态性与安徽地区胃癌易感性关系以及与胃癌临床病理特征和胃癌组织VEGF、环氧化酶-2(COX-2)蛋白表达的关系。方法采用基因测序仪对安徽地区238例胃癌患者及425例正常对照组血样进行VEGF rs3025039和rs3025021的多态性测序,用组织芯片技术及免疫组化法检测相应胃癌组织和30例癌旁组织中VEGF和COX-2的分布。结果与正常对照相比,胃癌患者VEGF rs3025039TT基因型可能增加胃癌风险性(P=0.047,OR=2.86,95%CI=1.01～8.08)。rs3025021CT基因型显著降低胃癌风险性(P=0.032,OR=0.65,95%CI=0.44～0.96)。胃癌组织VEGF和COX-2的阳性率分别为62.6%及61.8%,显著高于癌旁组织的26.7%(P=0.000)和36.7%(P=0.008),并与TNM分期、肿瘤大小、浸润深度、淋巴结转移、临床分期(仅VEGF)及组织学类型(仅COX-2)有关(P=0.001～0.05)。VEGF表达与COX-2呈正相关(rs=0.178,P=0.006)。除VEGF rs3025021与肿瘤大小有关(P=0.026)外,VEGF rs3025039和rs3025021与胃癌临床病理学参数及VEGF及COX-2表达均无关。结论VEGF rs3025039和rs3025021多态性影响安徽地区的胃癌易感性,对胃癌组织VEGF表达无明显影响;VEGF及COX-2表达与胃癌的肿瘤侵袭性密切相关,二者对胃癌的恶化进展可能有一定的协同作用。     

Predictive value of serum sST2 in preschool wheezers for development of asthma with high FeNO

Wheezing is common in childhood. However, current prediction models of pediatric asthma have only modest accuracy. Novel biomarkers and definition of subphenotypes may improve asthma prediction. Interleukin‐1‐receptor‐like‐1 (IL1RL1 or ST2) is a well‐replicated asthma gene and associates with eosinophilia. We investigated whether serum sST2 predicts asthma and asthma with elevated exhaled NO (FeNO), compared to the commonly used Asthma Prediction Index (API). Using logistic regression modeling, we found that serum sST2 levels in 2‐3 years‐old wheezers do not predict doctors’ diagnosed asthma at age 6 years. Instead, sST2 predicts a subphenotype of asthma characterized by increased levels of FeNO, a marker for eosinophilic airway inflammation. Herein, sST2 improved the predictive value of the API (AUC=0.70, 95% CI 0.56‐0.84), but had also significant predictive value on its own (AUC=0.65, 95% CI 0.52‐0.79). Our study indicates that sST2 in preschool wheezers has predictive value for the development of eosinophilic airway inflammation in asthmatic children at school age.     

血小板计数及纤维蛋白原水平与卵巢上皮性癌临床病理因素的相关性及其对预后的影响

目的:研究血小板计数及纤维蛋白原(fibrinogen,FIB)水平与卵巢上皮性癌临床病理因素之间的相关性及其对预后的影响.方法:选取2012年6月至2016年6月在连云港妇幼保健院住院手术的卵巢上皮性肿瘤患者297例,其中卵巢上皮性癌患者137例,卵巢上皮性良性肿瘤患者160例作为对照.回顾性分析卵巢上皮性癌患者的临床病理资料以及良性肿瘤患者的年龄、术前血常规、凝血功能,术后病理资料等.计算血小板及FIB增多在卵巢良恶性肿瘤中的发生率,以及其与卵巢上皮性癌患者临床病理因素之间的相关性;所有卵巢上皮性癌患者随访至2017年6月,计算其总生存期(overall survival,OS)及无进展生存期(progress-free survival,PFS),分析血小板及FIB增多与其预后的关系.结果:卵巢上皮性癌患者血小板及FIB含量显著高于卵巢良性肿瘤患者,差异有统计学意义(P<0.05).FIGO手术-病理分期越晚、分化程度越低、腹水量越多、术后残留肿瘤越大、术前CA125水平越高、术前肿瘤体积越小的患者合并血小板增多的发生率越高(P<0.05);FIB增多与FIGO手术-病理分期、腹水量、术后残留肿瘤大小及术前CA125水平有一定的相关性(P<0.05).血小板增多是卵巢上皮性癌患者PFS的独立不良预后因子(P<0.05).FIB增多与卵巢上皮性癌患者的预后无相关性.结论:血小板及FIB增多是卵巢上皮性癌常见现象之一,这可能与肿瘤的侵袭、转移相关;血小板增多是卵巢上皮性癌不良预后的危险因子.     

Expression of CCL18 and interleukin-6 in the plasma of breast cancer patients as compared with benign tumor patients and healthy controls

A growing body of laboratory research has shown that pro-inflammatory cytokines can facilitate tumor growth and metastasis. Our goal was to quantify the expression of CCL18 and IL-6 in patients with breast cancer compared with benign breast tumors patients and healthy women, in order to evaluate if these cytokines could serve for breast cancer diagnosis and evaluation. We also correlated the cytokines level of expression with some clinical and pathological characteristics known as prognostic markers for breast cancer. Plasma samples were obtained before treatment from 58 breast cancers, 41 benign breast tumors and 30 healthy women. The quantitative dosage was performed using ELISA. Wilcoxon test was used to compare groups. IL-6 and CCL18 were dramatically upregulated in breast cancers in comparison with healthy controls, but in comparison with benign tumors only CCL18÷PARC was overexpressed at borderline significance in cancers (p=0.05). The plasma from benign breast tumor patients exhibited also significant higher levels of the two cytokines than normal controls. The cytokines profile was not linked to patient age, tumor size, histopathological type, lymph node status or histological grade. IL-6 was significantly upregulated in ER-positive and metastasized cancers. CCL18÷PARC presented a significantly higher expression in advanced stage and highly proliferative carcinomas. In summary, IL-6 and CCL18 could clearly distinguish between women with breast cancers and healthy controls. High expression of IL-6 seems to confer a poor prognosis for ER-positive cancers. CCL18 was associated with worse prognosis parameters like high Ki67.     

CCL2, CCL3 and CCL4 gene polymorphisms in pulmonary tuberculosis patients of South India

Polymorphisms in chemokine genes are important to determine the host–pathogen interactions which influence the chemokine levels. This study was carried out to find whether various CC chemokine gene polymorphisms, located in the promoter, exon‐2 and intron‐1 regions are associated with susceptibility or resistance to pulmonary tuberculosis (PTB) in south Indian population. The polymorphisms in various CC chemokine genes, MCP‐1 (CCL2) [?2518A/G, 903C/T], MIP‐1α (CCL3) [?2021C/T, +740A/G] and MIP‐1β (CCL4) [?5725A/C] were studied in 295 healthy controls (HCs) and 303 patients with PTB using polymerase chain reaction‐based restriction fragment length polymorphism (PCR‐RFLP). The allele and genotype frequencies of CCL2, CCL3 and CCL4 were not different between HCs and patients with PTB. However, a significantly decreased frequency of CCL2 ?2518GG genotype was observed in male patients with PTB [P value = 0.015, P corrected (Bonferroni correction) Pc = 0.045, odds ratio (OR) 0.43 95% CI (0.21–0.86)], and a significantly increased frequency of the same genotype was observed among female patients with PTB [P value = 0.049, Pc = 0.147, OR 2.28 95% CI (1.00–5.27)]. The results suggest that ?2518GG genotype may be associated with protection in males and susceptibility to PTB in females. Moreover, we also observed differences in the haplotype frequencies of these chemokine genes between HCs and patients with PTB. However, these polymorphisms are not associated with disease independently, probably in combination with other genes, they may be associated with susceptibility or resistance to TB in south Indian population.     

Prognostic value of serum nicotinamide phosphoribosyltransferase in patients with bladder cancer

Aim

To analyze the serum nicotinamide phosphoribosyltransferase (Nampt) level and its prognostic value in bladder cancer (BC).

Methods

The study included 131 patients with transitional cell BC and 109 healthy controls from the West China Hospital of Sichuan University in the period between 2007 and 2013. Nampt concentration in serum was measured by commercial ELISA kits for human Nampt.

Results

The serum Nampt protein level in patients with BC (mean ± standard deviation, 16.02 ± 7.95 ng/mL) was significantly higher than in the control group (6.46 ± 2.08 ng/mL) (P < 0.001). Serum Nampt level was an independent prognostic marker of non-muscle-invasive BC, with a higher serum Nampt level (>14.74 ng/mL) indicating shorter recurrence-free survival rate (hazard ratio = 2.85, 95% confidence interval, 1.01-8.06; P = 0.048).

Conclusion

Our results suggest that serum Nampt level may serve as a biomarker of BC and an independent prognostic marker of non-muscle-invasive BC.Bladder cancer (BC) is the ninth most common cancer diagnosis worldwide (1) and the most expensive cancer to treat (2). Among men it is the fourth most common cancer, with incidence four times higher than in women (3). In China, BC caused 17 365 deaths in 2005, with a steady increase in mortality between 1991 and 2005 (4). Of newly diagnosed BC cases, 70%-80% will present with non-muscle-invasive disease, 50%-70% will recur despite endoscopic and intravesical treatments, and 10%-30% will progress to muscle-invasive disease (5,6). Most recurrences occur within 5 years (7). Therefore, to develop improved, more effective prevention and treatments there is a need to find new biomarkers of tumorigenesis and prognosis of BC.Nicotinamide phosphoribosyltransferase (Nampt) is a rate-limiting enzyme in the mammalian NAD⁺ biosynthesis of a salvage pathway (8). Previous studies have shown that it is significantly increased in primary colorectal cancer (9-11), lung cancer (12), breast cancer (13), prostate cancer (14) and gastric cancer (15). Thus, Nampt may be a good biomarker of malignant potential and stage progression (12,16). Our previous study revealed that genetic variants in NAMPT may predict BC risk and prognosis (17). In the present study, we analyzed the serum Nampt level and its prognostic value in BC.     

血清胃蛋白酶原与CA724联合检测在胃癌鉴别诊断中的应用价值

目的 探讨血清胃蛋白酶原(PG)和糖类抗原CA724联合检测作为肿瘤标志物用于胃癌鉴别诊断的可行性.方法 选取经纤维胃镜及病理组织学诊断为胃癌的患者195例,慢性萎缩性胃炎(CAG)患者175例,正常健康体检者210例.采用免疫分析法检测胃蛋白酶原Ⅰ(PG Ⅰ)、胃蛋白酶原Ⅱ(PGⅡ)并计胃蛋白酶原比值PGR(PG Ⅰ/PGⅡ),采用电化学发光免疫分析法检测糖化抗原CA724.结果 胃癌组PG Ⅰ与PGR水平明显低于正常对照组,两组比较差异具有统计学意义(P =0.000);PGⅡ的含量变化不大,两组比较差异无统计学意义(P =0.490).CAG组PG Ⅰ与PGR水平明显低于正常对照组,两组比较差异具有统计学意义(P =0.003);PGⅡ的含量变化不大,两组比较差异无统计学意义(P=0.407).胃癌组与CAG组PG Ⅰ与PGR比较差异无统计学意义(P =0.400).胃癌组的CA724水平明显高于CAG组与正常对照组,差异有统计学意义(P=0.003);而CAG组与正常对照组比较差异无统计学意义(P =0.388).对胃癌诊断的敏感性PC (71.79％)高于CA724(41.28％),特异性CA724 (92.2％)高于PG(66.23％),二者联合检测敏感性为82.67％,特异性为73.59％,同时阴性时82.78％排除胃癌诊断.结论 血清胃蛋白酶原和CA724联合检测二者同时阴性时可以82.78％排除胃癌诊断,可以作为胃癌鉴别诊断的标志物.     

Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis

Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease characterized by the predominant infiltration of T cells, eosinophils and macrophages in lesional skin. Recently, eotaxin-2/CCL24 and eotaxin-3/CCL26 were identified as CC chemokines that signal exclusively via the CCR3 receptor and have eosinophil-selective chemoattractant activity, as does eotaxin/CCL11. We previously reported that serum levels of thymus and activation-regulated chemokine (TARC)/CCL17 and macrophage-derived chemokine (MDC)/CCL22 were correlated with the severity of AD. In this report, we investigated the participation of eotaxin-2/CCL24 and eotaxin-3/CCL26 in AD, first measuring the serum levels of eotaxin-2/CCL24 and eotaxin-3/CCL26 in 30 patients with AD, 20 patients with psoriasis vulgaris and 20 healthy controls. The serum levels of eotaxin-3/CCL26 (but not eotaxin-2/CCL24) were significantly higher in patients with AD than in either healthy controls or patients with psoriasis vulgaris; furthermore, the eotaxin-3/CCL26 levels in patients with moderate and severe AD were significantly higher than eotaxin-3/CCL26 levels in patients with mild AD. The serum eotaxin-3/CCL26 levels tended to decrease after treatment, but there was no significant difference between groups. Moreover, the serum eotaxin-3/CCL26 levels were significantly correlated with the serum TARC/CCL17 and MDC/CCL22 levels, eosinophil numbers in peripheral blood and the scoring AD (SCORAD) index. Our study strongly suggests that serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, have a notable correlation with disease activity of AD and that eotaxin-3/CCL26, as well as TARC/CCL17 and MDC/CCL22, may be involved in the pathogenesis of AD.     

The prognostic value of preoperative serum levels of IL‐12p40 and IL‐23 for survival of patients with colorectal cancer

Colorectal cancer (CRC) patients were previously shown to express a signature of cytokines that contribute to cancer pathogenesis and are detectable in serum. The aim of this study was to evaluate the potential clinical use of circulating cytokine measurements in CRC patients preoperatively as markers for disease outcome. The levels of cytokines IL‐12p40 and IL‐23 were assessed by ELISA in the sera of 91 patients with previously untreated CRC and then 5‐year survival was determined using Kaplan–Meier analyses. The levels of circulating interleukin IL‐12p40 significantly decreased with the progression of CRC, whereas the levels of IL‐23 remained with no significant differences between disease stages. None of the cytokine levels were influenced by age, gender and colon vs rectum localization. We found that preoperative serum concentration of IL‐12p40 cytokine is a good prognostic marker for survival; as for IL‐23 levels, we found no outcome prognostic value. In addition, 5‐year survival confirmed that tumor grade, bowel wall invasion, lymph node and metastatic status have an impact on overall survival. In conclusion, we believe that our findings show clinical significance of the preoperative serum concentration for IL‐12p40 and provide an additional prognostic biomarker for CRC survival.     

血肌酐水平预测脑干出血预后的价值

目的确定判断脑干出血患者预后的血肌酐临界值,分析血肌酐与格拉斯哥昏迷评分（GCS）相关性,探讨血肌酐对评估脑干出血预后的价值。方法回顾性分析2010年6月至2012年6月期间本院收治的77例自发性脑干出血患者的临床资料,根据预后将患者分为生存组（n=51）和病死组（n=26）。对两组患者行GCS评分和血肌酐检测,根据血肌酐水平绘制血肌酐预测脑干出血患者病死情况的受试者工作曲线（ROC）并评估血肌酐的最优截断点cut-off值。以cut．off值为界将患者分为血肌酐〈96．000μmol／L组（n=39）和i〉96．000μmol／L组（n=38）,对比两组患者的GCS评分和实际病死率。结果病死组GCS评分低于生存组,而血肌酐水平高于生存组（均P〈0．05）。根据ROC曲线,以血肌酐水平来预测患者死亡事件,其cut．off值为96．000μmol／L,其诊断灵敏度为80．77％,特异度为66．67％。血肌酐〈96．000μmol／L组和I〉96．000μm01]L组患者的GCS评分及实际病死率差异均有统计学意义（均P〈0．05）。结论血肌酐水平可应用于脑干出血患者病情严重程度的评估以及预测死亡危险度。     

多西他赛联合奥沙利铂应用于胃癌术前辅助化疗的临床疗效对比

胃癌为常见的恶性肿瘤,发病率仅次于肺癌。由于胃癌早期缺乏特殊征象,确诊时一半以上人群己属晚期,手术后5年生存率也仅30%～40%。因此,如何提高进展期胃癌的疗效是目前研究热点之一。本文采用多西他赛联合奥沙利铂用于胃癌术前辅助化疗,取得了满意效果,现报告如下。     

血清D-二聚体、IL-6、IL-18对儿童难治性肺炎支原体

目的:探讨血清D-二聚体、白细胞介素-6(interleukin 6,IL-6)、白细胞介素-18(interleukin 18,IL-18)对儿童难治性肺炎支原体肺炎(refractory mycoplasma pneumoniae pneumonia,RMPP)的预测价值.方法:以2020年5月至2021年5月北京...     

胃癌患者血清IL-1的升高和癌组织JAK2/STAT3信号通路的激活

目的 探讨胃癌患者血清中白细胞介素1(IL-1)含量升高及癌组织中JAK2/STAT3信号通路激活在胃癌生长过程中的作用.方法 选取甘肃省武威肿瘤医院胃癌手术患者及同期健康体检者各30例;酶联免疫吸附法(ELISA)检测样本血清中IL-1和IL-10的含量;免疫组化和Western blot分别检测各组织中Bcl-2、...     

老年胃癌患者术后早期肠内营养的应用价值分析

目的 探讨早期肠内营养(EEN)支持治疗在老年胃癌患者术后的应用价值.方法 选取60例老年胃癌术后行EEN支持的患者作为EEN组,同期老年胃癌术后行全肠外营养(TPN)的患者40例为TPN组.比较2组患者肛门排气时间、口服进食时间、消化道症状发生率、并发症发生率、住院时间、血清蛋白、免疫球蛋白、电解质等变化情况.结果 EEN组出现肛门排气时间较TPN组显著缩短(P＜0.01);EEN组消化道症状出现率高于TPN组,经对症处理后消失;EEN组术后较术前体质量下降(1.8±0.2) kg,该下降值显著低于TPN组的(2.6±0.4) kg;EEN组住院时间较TPN组也明显缩短(P＜0.05).EEN组术后总蛋白、白蛋白及免疫球蛋白IgA显著高于TPN组(P＜0.01).EEN组电解质紊乱发生率显著低于TPN组(P＜0.05).结论 EEN营养支持适用于老年胃癌切除术患者,有助于改善患者的胃肠动力,缩短住院时间,维持机体免疫功能,有助于患者恢复.但容易出现胃肠道症状,需要控制输注速度和输入量.     

Predictive value of soluble haemoglobin scavenger receptor CD163 serum levels for survival in verified tuberculosis patients

Pre-treatment serum levels of sCD163 were measured in a cohort of 236 suspected tuberculosis (TB) cases from Guinea-Bissau, with a median follow-up period of 3.3 years (range 0-6.4 years). In 113 cases, the diagnosis of TB was verified by positive sputum microscopy and/or culture. Among the verified TB cases, a decreased survival rate was found in 27 patients with sCD163 levels above the upper reference limit (3.95 microg/mL). The difference in survival was significant during TB treatment (log rank, p<0.02) and after long-term follow-up (log rank, p<0.001). The decrease in survival rate during TB treatment remained significant in a multivariate Cox model controlling for human immunodeficiency virus (HIV) status, age and gender, with a mortality increase of 1.19 (95% CI, 1.04-1.36) per microg of sCD163, and a hazard ratio (HR) for sCD163 levels above the upper reference limit of 4.18 (95% CI, 1.06-16.4). The difference was not significant after excluding patients with concomitant HIV-1 and HIV-2 infection in Kaplan-Meier analyses (log rank, p 0.11). In contrast, the difference in survival remained significant in Kaplan-Meier analyses after long-term follow-up, even after excluding patients with concomitant HIV-1 and HIV-2 infection (log rank, p 0.002). In the Cox model, the mortality increase per microg of sCD163 was 1.27 (95% CI, 1.14-1.40), with an HR for elevated sCD163 levels of 2.85 (95% CI, 1.44-5.63). The HRs for concomitant HIV-1 and HIV-2 infection were 6.92 (95% CI, 3.28-14.58) and 2.48 (95% CI, 1.09-5.67), respectively. Thus, sCD163 levels appeared to be an independent predictor of survival in verified TB patients.     

Predictive factors in locally advanced rectal cancer treated with preoperative hyperfractionated and accelerated radiotherapy

This study examines the prognostic significance of pathologic factors in patients with primary locally advanced rectal cancer treated prospectively with preoperative radiotherapy. From 1992 to 1998, 104 patients with rectal cancer of grades T3 or T4 and any N underwent preoperative radiotherapy followed by surgical resection. Survival curves were estimated according to the Kaplan-Meier method. Correlation of outcome with clinicopathologic variables (pathologic tumor and lymph node staging, histology, radial resection margin [RRM], clearance, vessel involvement, and tumor regression grade [TRG], quantitated in 5 grades) was evaluated using the Cox proportional hazards model. None of the patients achieved a histologically confirmed complete pathologic response, but 79% of the patients showed partial tumor regression (TRG2-4) and 21% did not show any tumor regression (TRG5). Among the tumors, 22% were of a mucinous type. The RRM was free of tumor in 76% of the surgical specimens. The median clearance was 2 mm. Vascular invasion was present in 37 cases (36%). In the univariate analysis, lymph node metastases, absence of tumor regression, positive RRM, and vascular invasion were correlated with adverse overall survival and disease-free survival; absence of tumor regression, positive RRM, and clearance <2 mm were correlated with local recurrences; and advanced pT stage was correlated only with disease-free survival. However, in the multivariate analysis, only lymph node metastases and RRM were independent prognostic factors for overall survival and disease-free survival, and clearance <2 mm was an independent prognostic factor for local control. Pathologic parameters remain strong determinants of local recurrence and survival in locally advanced rectal cancer, treated preoperatively with hyperfractionated and accelerated radiotherapy. We show that patients with advanced pT, positive lymph nodes, vascular invasion, positive RRM, clearance <2 mm, or absence of tumor regression are known to have poor clinical outcome.